These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37309256)

  • 1. Blinded sample size recalculation in multiple composite population designs with normal data and baseline adjustments.
    Gera RG; Friede T
    Biom J; 2023 Oct; 65(7):e2000326. PubMed ID: 37309256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blinded sample size recalculation in clinical trials with binary composite endpoints.
    Sander A; Rauch G; Kieser M
    J Biopharm Stat; 2017; 27(4):705-715. PubMed ID: 27295402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials with nested subgroups: Analysis, sample size determination and internal pilot studies.
    Placzek M; Friede T
    Stat Methods Med Res; 2018 Nov; 27(11):3286-3303. PubMed ID: 29298604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stopping boundaries adjusted for sample size reestimation and negative stop.
    Shun Z
    J Biopharm Stat; 2002 Nov; 12(4):485-502. PubMed ID: 12477071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis.
    Friede T; Kieser M
    Pharm Stat; 2011; 10(1):8-13. PubMed ID: 19943322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size recalculation in multicenter randomized controlled clinical trials based on noncomparative data.
    Harden M; Friede T
    Biom J; 2020 Sep; 62(5):1284-1299. PubMed ID: 32128868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size calculation and blinded recalculation for analysis of covariance models with multiple random covariates.
    Zimmermann G; Kieser M; Bathke AC
    J Biopharm Stat; 2020; 30(1):143-159. PubMed ID: 31327284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blinded sample size recalculation in adaptive enrichment designs.
    Placzek M; Friede T
    Biom J; 2023 Feb; 65(2):e2000345. PubMed ID: 35983952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blinded and unblinded internal pilot study designs for clinical trials with count data.
    Schneider S; Schmidli H; Friede T
    Biom J; 2013 Jul; 55(4):617-33. PubMed ID: 23703749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blinded sample size recalculation in multicentre trials with normally distributed outcome.
    Jensen K; Kieser M
    Biom J; 2010 Jun; 52(3):377-99. PubMed ID: 20394080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels.
    Żebrowska M; Posch M; Magirr D
    Stat Med; 2016 May; 35(12):1972-84. PubMed ID: 26694878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blinded sample size reestimation for negative binomial regression with baseline adjustment.
    Zapf A; Asendorf T; Anten C; Mütze T; Friede T
    Stat Med; 2020 Jun; 39(14):1980-1998. PubMed ID: 32207171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smoothing Corrections for Improving Sample Size Recalculation Rules in Adaptive Group Sequential Study Designs.
    Herrmann C; Rauch G
    Methods Inf Med; 2021 May; 60(1-02):1-8. PubMed ID: 33648007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalence.
    Maurer W; Jones B; Chen Y
    Stat Med; 2018 May; 37(10):1587-1607. PubMed ID: 29462835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sample size determination in group-sequential clinical trials with two co-primary endpoints.
    Asakura K; Hamasaki T; Sugimoto T; Hayashi K; Evans SR; Sozu T
    Stat Med; 2014 Jul; 33(17):2897-913. PubMed ID: 24676799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size of thorough QTc clinical trial adjusted for multiple comparisons.
    Tsong Y; Sun A; Kang SH
    J Biopharm Stat; 2013; 23(1):57-72. PubMed ID: 23331221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extension of a conditional performance score for sample size recalculation rules to the setting of binary endpoints.
    Bokelmann B; Rauch G; Meis J; Kieser M; Herrmann C
    BMC Med Res Methodol; 2024 Jan; 24(1):15. PubMed ID: 38243169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new conditional performance score for the evaluation of adaptive group sequential designs with sample size recalculation.
    Herrmann C; Pilz M; Kieser M; Rauch G
    Stat Med; 2020 Jul; 39(15):2067-2100. PubMed ID: 32249968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Group sequential designs with prospectively planned rules for subpopulation enrichment.
    Rosenblum M; Luber B; Thompson RE; Hanley D
    Stat Med; 2016 Sep; 35(21):3776-91. PubMed ID: 27076411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.